Talphera (TLPH) Long-Term Debt Issuances (2011)
Talphera's (TLPH) quarterly Long-Term Debt Issuances came in at $10.0 million in Q4 2011.
Talphera (TLPH) Long-Term Debt Issuances (2011) Analysis & Trends
Talphera's Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $10.0 million for Q4 2011.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $10.0 million in Q4 2011; TTM through Sep 2019 was $10.0 million, a N/A change from a year earlier, with the FY2019 full-year figure at $25.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances steadied at $10.0 million in Q4 2011 per TLPH's latest filing.
- Across five years, Long-Term Debt Issuances topped out at $10.0 million in Q4 2011 and bottomed at $10.0 million in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.64 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 10.00 Mn |
| Dec 31, 2011 | 10.00 Mn |